The Post-Patent Play: A Petition to Reshape the Value of Medicine

SPOKANE, WA – August 25, 2026 – The established lifecycle of a blockbuster drug—from discovery to protected blockbuster to eventual generic competition—may be facing its most significant challenge in decades. A Citizen Petition filed today with the U.S. Food and Drug Administration (FDA) proposes a fundamental rethinking of how we determine value and create competition for medicines once their legal monopoly ends.

Professor Sarfaraz K. Niazi of Washington State University, a veteran of regulatory science with a history of influencing FDA policy, is the architect of this potentially transformative proposal. His petition, titled "Request to Establish a Unified Reference-Anchored Equivalence Framework," asks the FDA to apply the scientific logic that underpins generic and biosimilar drugs to nearly every medicine it has ever approved. This includes the most complex and expensive treatments on the market, from monoclonal antibodies and vaccines to next-generation gene and cell therapies.

The core of Niazi's argument is a principle he calls "reference-anchored equivalence." It posits that if a new manufacturer can prove its product is scientifically indistinguishable from an existing, FDA-approved medicine through advanced analytical testing, it should not be forced to repeat costly and time-consuming clinical efficacy trials that offer no new scientific insight. This isn't a call for lower standards, the petition insists, but for more intelligent ones.

A New Scientific Yardstick

The modern pharmaceutical landscape was built on the Hatch-Waxman Act of 1984, which created the abbreviated pathway for generic drugs. It established a paradigm: once a drug's safety and efficacy are known, subsequent versions need only prove they are chemically and biologically equivalent, not re-prove the original clinical benefit. This simple principle has saved the U.S. healthcare system trillions of dollars.

More recently, the Biologics Price Competition and Innovation Act (BPCIA) extended this concept to complex biological drugs, creating the biosimilar pathway. The FDA, partly through Niazi's prior advocacy, has increasingly accepted that sophisticated analytical and functional comparisons can often replace the need for large-scale comparative clinical trials for these products.

Niazi's petition asks a powerful question: Why stop there? If science can sufficiently de-risk a follow-on product and confirm its similarity to a reference drug, why should its regulatory classification—as a protein, a vaccine, or a nucleic-acid product—automatically trigger a mandate for redundant human trials?

"The principle is not that clinical trials should be eliminated," Niazi stated in the press release. "Rather, the fundamental principle is that each experiment must serve a genuine scientific purpose." He argues that forcing a manufacturer to conduct large efficacy trials "solely out of conventional practice leads to the unnecessary utilization of patient participants, significant time expenditure, and considerable resources, without necessarily improving the robustness of regulatory decisions."

This proposed framework is not a rubber stamp. It demands a rigorous, product-specific evaluation. A manufacturer would have to demonstrate that any new risks from its own process are independently assessed. If scientific uncertainty remains, the FDA retains full authority to demand more data, including clinical trials. The goal is to make the evidence fit the question, not the historical category of the drug.

The Economics of Equivalence

The petition's implications extend far beyond the laboratory, striking at the heart of the pharmaceutical business model. For many of today's most expensive biologicals and advanced therapies, the high cost and complexity of development serve as a formidable barrier to entry, creating de facto monopolies that persist long after patents and regulatory exclusivities expire.

By potentially slashing the cost and time required to bring follow-on versions to market, the framework could ignite competition in previously untouchable therapeutic areas. While innovator companies, represented by groups like PhRMA, argue that robust intellectual property protections and high bars for follow-on products are essential to incentivize the risky, billion-dollar-plus investment in R&D, proponents of Niazi's approach see it differently.

They argue the system should reward innovation during its protected period, but not create artificial scientific hurdles that prevent competition indefinitely. "Patent and exclusivity protections should appropriately reward innovation in accordance with Congress's original intent," Niazi noted. "However, once these protections cease to hinder competition, it is unnecessary to impose an additional scientific obstacle by mandating the repetition of experiments that no longer yield beneficial insights."

Organizations representing generic and biosimilar manufacturers, such as the Biosimilars Council, have long advocated for policies that streamline approval and boost uptake, pointing to projections of over $180 billion in savings from biosimilars in the coming years. Niazi's framework would dramatically expand that potential, creating a more resilient and competitive market for follow-on medicines.

From Lab to the World: The Global Mandate

While the petition is directed at the U.S. FDA, its shockwaves would be global. The FDA is the world's premier regulatory agency, and its standards set the tone for drug development, investment, and market access worldwide. Adopting a scientifically rigorous, abbreviated pathway for complex follow-on drugs could create a viable path for manufacturers in lower-cost regions to enter markets previously beyond their reach.

The greatest impact could be felt in lower- and middle-income countries. For Niazi, this is the ultimate public health imperative.

"Scientific innovation has furnished us with remarkable therapies, but an invention that remains economically inaccessible to the majority of humanity has not fulfilled its public health mission," he stated. "A treatment that exceeds the financial capabilities of a nation or a family effectively equates to having no treatment at all for the affected patients."

By lowering a key barrier to market entry—redundant development costs—the proposal could foster a more diverse and resilient global supply chain. This would reduce reliance on single-source manufacturers for medically critical products, a vulnerability laid bare during recent global health crises.

The Regulatory Crossroads

Professor Niazi's proposal now enters the formal, and often lengthy, FDA Citizen Petition process. The immediate question is one of authority. Does the FDA have the legal power under the existing Federal Food, Drug, and Cosmetic Act and Public Health Service Act to implement such a sweeping, unified framework through new regulations and guidance, or would it require an act of Congress?

The agency has shown increasing flexibility within the biosimilar pathway, but extending that logic to all drug classes, especially those with unique statutory definitions like gene therapies, may test the limits of its administrative discretion. The petition anticipates this, respectfully requesting that if the FDA finds its hands are tied by law, it should explicitly identify those statutory barriers and advise Congress on how to remove them.

This places the FDA at a critical juncture. It must weigh the immense public health potential of increased access and affordability against the deeply entrenched interests of the innovator industry and the legitimate scientific complexities of novel therapies. The agency's response will signal its vision for the future of drug regulation in an era of unprecedented scientific capability and pressing economic realities.